Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERINO: Piperacillin-Tazobactam vs Meropenem
NCT02176122Phase 4Terminated
- Sponsor
- The University of Queensland
- Start
- Feb 2014
- Primary completion
- Jul 2017
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 9
01
Overview
Phase 4, randomised, open-label trial of piperacillin + tazobactam in bloodstream infection (BSI) (2 arms), sponsored by The University of Queensland. Primary endpoint: Mortality at 30 days. Started Feb 2014; status: terminated.
02
Drugs
piperacillin + tazobactam
03
Conditions
bloodstream infection (BSI)
Beyond the preview
Go deeper on NCT02176122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02176122.